Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12233091-B2
Publication Date
2025-02-25
Expiration Date
Abstract
The present invention relates to pharmaceutical vaccine compositions comprising at least one vaccine antigen together with living immune cells. These immune cells include at least a portion of activated T-cells and act as an adjuvant. Methods for using these pharmaceutical compositions to prevent or treat diseases, such as cancer, infectious diseases and autoimmune disease are also included.
Core Innovation
The invention provides a method for reducing antigens from a tumor in a host by administering a pharmaceutical composition that includes an adjuvant and one or more antigens. The antigen source is chaperone rich cell lysates (CRCL) obtained from the tumor, where the CRCL comprises multiple chaperone complexes enriched by free solution-isoelectric focusing, including GRP94/gp96, HSP90, HOSP70, and calreticulin.
The adjuvant comprises living immune cells that are allogeneic to the host and includes activated T-cells comprising memory Th1 cells activated by cross-linking CD3 and CD28 surface molecules. The activated T-cells express CD40L. After administration, the pharmaceutical composition stimulates a Th1 immune response in the host to the one or more antigens in the composition, thereby stimulating a Th1 immune response in the host against the antigens from the tumor.
The invention further specifies administration formats and timing, including embodiments in which the pharmaceutical composition is administered with the adjuvant and the antigens combined prior to administering to the host, or alternatively administered sequentially. Booster embodiments are also described, where a booster composition includes living immune cells with at least part activated T-cells and is administered at least about 7 days after the pharmaceutical composition.
Claims Coverage
The partial set of information identifies one independent claim directed to a tumor antigen reduction method using CRCL antigens enriched by free solution-isoelectric focusing together with living allogeneic activated memory Th1 T-cell adjuvant activated by CD3/CD28 cross-linking. Dependent claims refine the antigen composition and activation/expression and specify combined versus sequential administration and booster timing.
Tumor-derived CRCL antigens enriched by free solution-isoelectric focusing
The method reduces antigens from a tumor in a host by administering a pharmaceutical composition where the source of one or more antigens is chaperone rich cell lysates (CRCL) from the tumor, and the CRCL comprises multiple chaperone complexes enriched by free solution-isoelectric focusing, the multiple chaperone complexes comprising GRP94/gp96, HSP90, HOSP70 and calreticulin.
Living allogeneic activated memory Th1 T-cell adjuvant activated by CD3/CD28 cross-linking
The adjuvant comprises living immune cells that comprise activated T-cells that are allogeneic to the host, where the T-cells comprise memory Th1 cells activated by cross-linking CD3 and CD28 surface molecules.
Stimulation of Th1 immune response against tumor antigens from the composition
The pharmaceutical composition, upon administration to the host, stimulates a Th1 immune response in the host to the one or more antigens in the composition, thereby stimulating a Th1 immune response in the host against the antigens from the tumor.
CD40L expression by activated T-cells
The activated T-cells express CD40L.
Combined administration of adjuvant and antigens
The adjuvant and the one or more antigens are combined prior to administering to the host.
Sequential administration of adjuvant and antigens
The adjuvant and the one or more antigens are administered sequentially to the host.
Tumor associated antigens as the antigen set
One or more antigens further comprise tumor associated antigens.
Booster administered at least about 7 days after the pharmaceutical composition
A booster composition comprising living immune cells with at least part activated T-cells is administered at least about 7 days after the pharmaceutical composition.
Overall, the independent claim coverage centers on using tumor-derived CRCL antigens enriched by free solution-isoelectric focusing together with living, allogeneic activated memory Th1 T-cells activated by CD3/CD28 cross-linking, with the composition designed to stimulate a Th1 immune response against tumor antigens; dependent features refine antigen type, T-cell expression, administration format, and booster timing.
Stated Advantages
Documented Applications
No documented applications found
Interested in licensing this patent?